Article
Clinical Neurology
Joakim Bergman, Joachim Burman, Tommy Bergenheim, Anders Svenningsson
Summary: The study evaluated the effect of intrathecally delivered rituximab on PMS and found that it was well tolerated but did not halt disease progression.
JOURNAL OF NEUROLOGY
(2021)
Article
Hematology
Philip A. Thompson, Alexandre Bazinet, William G. Wierda, Constantine S. Tam, Susan M. O'Brien, Satabdi Saha, Christine B. Peterson, William Plunkett, Michael J. Keating
Summary: Chemoimmunotherapy with FCR achieves durable remissions, especially in patients with mutated immunoglobulin heavy chain variable gene (IGHV-M). The median progression-free survival (PFS) for IGHV-M patients is 14.6 years, compared to 4.2 years for patients with unmutated IGHV (IGHV-UM). A risk-benefit assessment is necessary when counseling patients.
Review
Rheumatology
Beatriz Frade-Sosa, Ana Belen Azuaga, Virginia Ruiz-Esquide, Jose A. Gomez-Puerta, Raimon Sanmarti
Summary: This study reported a case of a patient with rheumatoid arthritis who had pulmonary rheumatoid nodules diagnosed while receiving etanercept and experienced complete resolution of the nodules after 5 years of rituximab treatment.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Immunology
Ramon Diez-Feijoo, Juan Jose Rodriguez-Sevilla, Concepcion Fernandez-Rodriguez, Solange Flores, Carmen Raya, Ana Ferrer, Luis Colomo, Antonio Salar
Summary: Late onset neutropenia (LON), defined as unexplained neutropenia after rituximab or rituximab plus chemotherapy, is rare and its pathophysiology is unknown. There is no consensus on the optimal management for LON. Most patients recover without specific treatment, while some may require granulocytic colony stimulating factor (G-CSF) for rapid response.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Marcus W. Koch, Kayla Sage, Sharanjit Kaur, Janet Kim, Graziela Cerchiaro, V. Wee Yong, Gary R. Cutter, Luanne M. Metz
Summary: The study did not demonstrate the efficacy of domperidone treatment in reducing disability progression in SPMS patients, but found that patients with higher prolactin levels during the study had a lower risk of disability progression.
Article
Infectious Diseases
Fabrizio Di Maida, Lorenzo Viola, Luca Lambertini, Andrea Mari, Jessica Mencarini, Beatrice Borchi, Marco Carini, Lorenzo Zammarchi, Andrea Minervini
Summary: This case report highlights the potential role of JC virus in urinary tract involvement after rituximab treatment. The patient developed severe renal and urinary tract complications attributed to JC virus reactivation, indicating a possible association between long-term rituximab treatment and JC virus-related diseases.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Clinical Neurology
Giacomo Boffa, Luca Massacesi, Matilde Inglese, Alice Mariottini, Marco Capobianco, Lucia Moiola, Maria Pia Amato, Salvatore Cottone, Francesca Gualandi, Marco De Gobbi, Raffaella Greco, Rosanna Scime, Jessica Frau, Giovanni Bosco Zimatore, Antonio Bertolotto, Giancarlo Comi, Antonio Uccelli, Alessio Signori, Emanuele Angelucci, Chiara Innocenti, Fabio Ciceri, Anna Maria Repice, Maria Pia Sormani, Riccardo Saccardi, Gianluigi Mancardi
Summary: The study analyzed the long-term outcomes of autologous hematopoietic stem cell transplantation in patients with multiple sclerosis, showing that it prevents disability worsening in most patients and induces durable improvement in disability in patients with relapsing-remitting MS. The BEAM+ ATG conditioning protocol was found to be associated with a more pronounced suppression of clinical relapses and MRI inflammatory activity.
Article
Immunology
Jiali Cheng, Jin Huang, Wenyue Cao, Liang Huang, Xia Mao, Liting Chen, Jianfeng Zhou, Na Wang
Summary: CMV infection/reactivation can occur in patients long after receiving anti-CD19/22 CAR-T cell therapy, and induce fatal pneumonia, which reminds us of the late side effects associated with immunosuppression after CAR-T cell infusion.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Rheumatology
Roba Ghossan, Omar Al Tabaa, Alice Combier, Alexia Steelandt, Marion Thomas, Olivier Fogel, Corinne Miceli-Richard, Anna Molto, Yannick Allanore, Jerome Avouac
Summary: Maintaining complete B cell (BC) depletion does not appear to be a therapeutic target to achieve in rheumatoid arthritis (RA) patients in long-term maintenance therapy with rituximab (RTX).
Article
Physiology
Bernardino Clavo, Delvys Rodriguez-Abreu, Saray Galvan, Mario Federico, Gregorio Martinez-Sanchez, Yolanda Ramallo-Farina, Carla Antonelli, Gretel Benitez, Dolores Rey-Baltar, Ignacio J. Jorge, Francisco Rodriguez-Esparragon, Pedro Serrano-Aguilar
Summary: This report demonstrates the potential of ozone treatment as a modulator of oxidative stress in chronic pain secondary to chemotherapy-induced peripheral neuropathy (CIPN), leading to clinically relevant and long-lasting improvement in pain symptoms.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Multidisciplinary Sciences
Jinnam Kim, Changhyup Kim, Jung Ah Lee, Se Ju Lee, Ki Hyun Lee, Jung Ho Kim, Jin Young Ahn, Su Jin Jeong, Nam Su Ku, Jun Yong Choi, Joon-Sup Yeom, Young Goo Song
Summary: Progressive multifocal leukoencephalopathy (PML) is a rare but fatal opportunistic infection mainly occurring in patients with immunosuppressive conditions. Retrospective studies have shown that the survival rate of PML patients is related to HIV infection, and early diagnosis and treatment can improve prognosis.
SCIENTIFIC REPORTS
(2023)
Article
Medicine, General & Internal
Stjepan Jurisic, Mathis Komminoth, Atanas Todorov, Daniela A. Bertschi, Martin Jurisic, Ivica Vranjic, Benedikt Wiggli, Hansruedi Schmid, Catherine Gebhard, Caroline E. Gebhard, Bettina Heidecker, Juerg-Hans Beer, Dimitri Patriki
Summary: In patients with COVID-19, new-onset atrial fibrillation is associated with an increased risk of invasive ventilation and transfer to the intermediate/intensive care unit (IMC/ICU), but does not affect in-hospital or long-term mortality.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Chemistry, Analytical
Goncalo J. Gouveia, Amanda O. Shaver, Brianna M. Garcia, Alison M. Morse, Erik C. Andersen, Arthur S. Edison, Lauren M. McIntyre
Summary: The study developed stable and sustainable reference materials (RM) using the iterative batch averaging method (IBAT), which was then applied in a metabolomics experiment to estimate the proportion of sample variation.
ANALYTICAL CHEMISTRY
(2021)
Article
Cell Biology
Neil S. N. Graham, Karl A. Zimmerman, Federico Moro, Amanda Heslegrave, Samia Abed Maillard, Adriano Bernini, John-Paul Miroz, Cornelius K. Donat, Maria Yanez Lopez, Niall Bourke, Amy E. Jolly, Emma-Jane Mallas, Eyal Soreq, Mark H. Wilson, Gavin Fatania, Dylan Roi, Maneesh C. Patel, Elena Garbero, Giovanni Nattino, Camelia Baciu, Enrico Fainardi, Arturo Chieregato, Primoz Gradisek, Sandra Magnoni, Mauro Oddo, Henrik Zetterberg, Guido Bertolini, David J. Sharp
Summary: Plasma NfL serves as a sensitive and clinically meaningful measure of axonal injury resulting from TBI, validated through advanced MRI, cerebral microdialysis, and experimental models. The results support the incorporation of NfL sampling into clinical practice to aid in diagnosis and improve prognosis.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Medicine, General & Internal
Naoto Imoto, Daisuke Koyama, Isamu Sugiura, Shingo Kurahashi
Summary: RB may be a treatment option for patients with relapsed or refractory HCL-v, but further research is needed to establish the optimal treatment regimen for these patients.
Article
Clinical Neurology
Valerie J. Block, Erica A. Pitsch, Arpita Gopal, Chao Zhao, Mark J. Pletcher, Gregory M. Marcus, Jeffrey E. Olgin, Jill Hollenbach, Riley Bove, Bruce A. C. Cree, Jeffrey M. Gelfand
Summary: Falling is common in people with MS, but tends to be under-ascertained and under-treated. Those who fall tend to have greater disability, are more likely to have progressive MS, and take fewer steps on average. Multimodal fall screening may help identify those at greatest risk and improve patient care.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Hans-Peter Hartung, Tobias Derfuss, Bruce A. C. Cree, Maria Pia Sormani, Krzysztof Selmaj, Jonathan Stutters, Ferran Prados, David MacManus, Hans-Martin Schneble, Estelle Lambert, Herve Porchet, Robert Glanzman, David Warne, Francois Curtin, Gabrielle Kornmann, Benedicte Buffet, David Kremer, Patrick Kury, David Leppert, Thomas Ruckle, Frederik Barkhof
Summary: The study did not meet its primary endpoint, but at 48 weeks participants treated with 18 mg/kg temelimab had fewer new T1-hypointense lesions. They also showed consistent, although statistically non-significant, reductions in brain atrophy and magnetization transfer ratio decrease compared to the placebo/comparator group. These trends were sustained over 96 weeks with no safety issues emerging.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Review
Clinical Neurology
Bruce A. C. Cree, Douglas L. Arnold, Jeremy Chataway, Tanuja Chitnis, Robert J. Fox, Angela Pozo Ramajo, Niamh Murphy, Hans Lassmann
Summary: In most cases, multiple sclerosis begins with a relapsing-remitting course followed by secondary progressive MS (SMPS), and there are major differences between RRMS and SPMS in terms of treatment response and diagnosis. However, clear criteria marking the transition from RRMS to SPMS have not been established yet. Early identification of SPMS will require tools that, along with appropriate treatment, may lead to better long-term outcomes.
Article
Clinical Neurology
Roseanne Sullivan, Ajay Kilaru, Bernhard Hemmer, Bruce Anthony Campbell Cree, Benjamin M. Greenberg, Uma Kundu, Thomas Hach, Virginia DeLasHeras, Brian J. Ward, Joseph Berger
Summary: A descriptive analysis of COVID-19 infection in patients with multiple sclerosis receiving fingolimod or siponimod revealed that the risk of more severe COVID-19 in these patients seems to be similar to that reported in the general population and the MS population with COVID-19. However, limitations of spontaneous reporting, especially missing data, should be considered in the interpretation of these observations.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2022)
Article
Clinical Neurology
Bruce A. C. Cree, Douglas L. Arnold, Robert J. Fox, Ralf Gold, Patrick Vermersch, Ralph H. B. Benedict, Amit Bar-Or, Daniela Piani-Meier, Nicolas Rouyrre, Shannon Ritter, Ajay Kilaru, Goeril Karlsson, Gavin Giovannoni, Ludwig Kappos
Summary: This study evaluated the long-term efficacy and safety of siponimod in the treatment of SPMS. The results showed that continuous use of siponimod reduced the risk of disability progression and worsening in cognitive processing speed, and sustained efficacy was observed in relapse rate, brain atrophy, and inflammatory disease activity. No new safety signals were identified over the long term.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Douglas L. Arnold, Daniela Piani-Meier, Amit Bar-Or, Ralph H. B. Benedict, Bruce A. C. Cree, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Sophie Arnould, Frank Dahlke, Thomas Hach, Shannon Ritter, Goeril Karlsson, Ludwig Kappos, Robert J. Fox
Summary: The study found that siponimod treatment can slow down brain tissue damage and myelination process in patients with multiple sclerosis. This provides important information for better understanding of brain tissue integrity in patients with multiple sclerosis.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Review
Clinical Neurology
Stanley L. Cohan, Ralph H. B. Benedict, Bruce A. C. Cree, John DeLuca, Le H. Hua, Jerold Chun
Summary: Siponimod is an approved oral treatment for relapsing forms of multiple sclerosis, which targets the immune response and neural inflammation through regulating S1P(1) and S1P(5) receptors. It reduces lymphocyte migration to the central nervous system and exerts effects on various brain cells to decrease neurodegeneration and damage.
Article
Clinical Neurology
Bruce A. C. Cree, Krzysztof W. Selmaj, Lawrence Steinman, Giancarlo Comi, Amit Bar-Or, Douglas L. Arnold, Hans-Peter Hartung, Xavier Montalban, Eva K. Havrdova, James K. Sheffield, Neil Minton, Chun-Yen Cheng, Diego Silva, Ludwig Kappos, Jeffrey A. Cohen
Summary: This study characterizes the long-term safety and efficacy of ozanimod in the treatment of relapsing forms of multiple sclerosis. The findings confirm a favorable safety profile and sustained benefit in clinical outcomes and magnetic resonance imaging measures of disease activity.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Letter
Clinical Neurology
Bruce A. C. Cree, Benjamin Greenberg, Chris Cameron, Brian G. Weinshenker
NEUROLOGY AND THERAPY
(2022)
Article
Clinical Neurology
Hari V. V. Kalluri, Matthew R. R. Rosebraugh, Thomas P. P. Misko, Adam Ziemann, Wei Liu, Bruce A. C. Cree
Summary: This study focuses on the safety, tolerability, pharmacokinetics, and immunogenicity of elezanumab in healthy individuals and multiple sclerosis patients. The results demonstrate that elezanumab does not cause adverse events and has dose-dependent increases in cerebrospinal fluid concentrations.
ANNALS OF NEUROLOGY
(2023)
Editorial Material
Clinical Neurology
Bruce A. C. Cree
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Riley Bove, Shane Poole, Richard Cuneo, Sasha Gupta, Joseph Sabatino, Meagan Harms, Tifffany Cooper, William Rowles, Nicolette Miller, Refujia Gomez, Robin Lincoln, Kira McPolin, Kyra Powers, Adam Santaniello, Adam Renschen, Carolyn J. Bevan, Jeffrey M. Gelfand, Douglas S. Goodin, Chu-Yueh Guo, Andrew R. Romeo, Stephen L. Hauser, Bruce Anthony Campbell Cree, UCSF MS-EPIC Team
Summary: This study found that remote evaluations can reduce the costs of research participation for patients, while providing a reasonable evaluation of disability trajectory longitudinally. This could inform the design of remote research that is more inclusive of diverse participants.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2023)
Review
Clinical Neurology
Tjalf Ziemssen, Virender Bhan, Jeremy Chataway, Tanuja Chitnis, Bruce Anthony Campbell Cree, Eva Kubala Havrdova, Ludwig Kappos, Pierre Labauge, Aaron Miller, Jin Nakahara, Celia Oreja-Guevara, Jacqueline Palace, Barry Singer, Maria Trojano, Ashwini Patil, Benedict Rauser, Thomas Hach
Summary: There are many challenges in accurately diagnosing and managing SPMS due to the lack of definitive criteria for the transition from RRMS to SPMS. This review discusses the diagnostic criteria/definition and the heterogeneity of SPMS patient populations, and emphasizes the importance of early identification through prospective/retrospective tools to improve outcomes with approved treatments. Effective interventions require ongoing patient-clinician dialogue within a multidisciplinary team.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2023)
Article
Clinical Neurology
Bruce A. C. Cree, Rachel Maddux, Amit Bar-Or, Hans-Peter Hartung, Amandeep Kaur, Elizabeth Brown, Yicong Li, Yanhua Hu, James K. Sheffield, Diego Silva, Sarah Harris
Summary: This study investigated the serologic response, predictors of response, and clinical outcomes associated with SARS-CoV-2 vaccination and infection in RMS patients treated with ozanimod. The results showed that most ozanimod-treated RMS patients mounted a serologic response to SARS-CoV-2 vaccination and infection, regardless of individual characteristics or lymphocyte count levels. Additionally, mRNA vaccination predicted higher levels of serum antibodies.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2023)
Article
Clinical Neurology
Valerie J. Block, Riley Bove, Jeffrey M. Gelfand, Bruce A. C. Cree
Summary: Wrist-worn activity monitors can track the impact of environmental changes on physical activity in real time.
NEUROLOGY-CLINICAL PRACTICE
(2021)